


PHARMACEUTICAL 2021



MARIZYME INC Rank 50 of 409







PHARMACEUTICAL 2021

MARIZYME INC Rank 50 of 409



The relative strengths and weaknesses of MARIZYME INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARIZYME INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 728% points. The greatest weakness of MARIZYME INC is the variable Other Expenses, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 107%, being 461% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	3,106
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	721
Liabilities, Non-Current	1,075
Other Assets	43,970
Other Compr. Net Income	0
Other Expenses	5,997
Other Liabilities	0
Other Net Income	-45
Property and Equipment	7.1
Research and Development	0
Revenues	197
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	47,084
Liabilities	1,796
Expenses	5,997
Stockholders Equity	45,288
Net Income	-5,845
Comprehensive Net Income	-5,845
Economic Capital Ratio	107%

